Lung cancer patients in the UK are closer to gaining access to a new targeted treatment Giotrif® (afatinib), the first oncology treatment to be developed by Boehringer Ingelheim. The National Institute for Health and Care Excellence (NICE) has issued the Final Appraisal Determination (FAD) recommending afatinib as a first line treatment "for treating epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small cell lung cancer".
More...
More...